JP2023548310A5 - - Google Patents

Info

Publication number
JP2023548310A5
JP2023548310A5 JP2023526266A JP2023526266A JP2023548310A5 JP 2023548310 A5 JP2023548310 A5 JP 2023548310A5 JP 2023526266 A JP2023526266 A JP 2023526266A JP 2023526266 A JP2023526266 A JP 2023526266A JP 2023548310 A5 JP2023548310 A5 JP 2023548310A5
Authority
JP
Japan
Prior art keywords
therapeutic
pharmaceutical product
product according
moiety
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526266A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548310A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/057330 external-priority patent/WO2022094262A1/en
Publication of JP2023548310A publication Critical patent/JP2023548310A/ja
Publication of JP2023548310A5 publication Critical patent/JP2023548310A5/ja
Pending legal-status Critical Current

Links

JP2023526266A 2020-10-30 2021-10-29 Fap活性化血清半減期延長型治療用コンジュゲート Pending JP2023548310A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063108020P 2020-10-30 2020-10-30
US63/108,020 2020-10-30
US202163197926P 2021-06-07 2021-06-07
US63/197,926 2021-06-07
PCT/US2021/057330 WO2022094262A1 (en) 2020-10-30 2021-10-29 Fap-activated serum extended half-life therapeutic conjugates

Publications (2)

Publication Number Publication Date
JP2023548310A JP2023548310A (ja) 2023-11-16
JP2023548310A5 true JP2023548310A5 (cg-RX-API-DMAC7.html) 2024-09-20

Family

ID=78819635

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526266A Pending JP2023548310A (ja) 2020-10-30 2021-10-29 Fap活性化血清半減期延長型治療用コンジュゲート

Country Status (6)

Country Link
US (1) US20230390409A1 (cg-RX-API-DMAC7.html)
EP (1) EP4237012A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023548310A (cg-RX-API-DMAC7.html)
KR (1) KR20230141754A (cg-RX-API-DMAC7.html)
TW (1) TW202227139A (cg-RX-API-DMAC7.html)
WO (1) WO2022094262A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
US20230381330A1 (en) * 2020-10-30 2023-11-30 Avacta Life Sciences Limited Enzyme-activated serum extended half-life therapeutic conjugates
JP2025521779A (ja) * 2022-07-05 2025-07-10 ゾウネック、アレックス 多段階化学療法用のプロドラッグキット
WO2026002995A1 (en) 2024-06-24 2026-01-02 Avacta Life Sciences Limited Target-specific fap-activated topoisomerase inhibitor conjugates and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
CA2786794C (en) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
BRPI0811125A2 (pt) 2007-05-08 2017-05-09 Astrazeneca Ab imidazoquinolinas com propriedades imunomoduladoras
EP3543256A1 (en) * 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US8828678B2 (en) 2010-11-16 2014-09-09 Enzo Life Sciences, Inc. Self-immolative probes for enzyme activity detection
KR20210132742A (ko) 2012-12-21 2021-11-04 알트루바이오 인코퍼레이티드 친수성 자기-희생 링커 및 그것의 포합체
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
WO2015038426A1 (en) 2013-09-13 2015-03-19 Asana Biosciences, Llc Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 癌処置としてのstingアゴニストの使用
JP6539729B2 (ja) * 2014-06-03 2019-07-03 ジアリー・ファーマシューティカルズ・インコーポレイテッドJiaray Pharmaceuticals, Inc. ペプチド−薬物複合体
IL325256A (en) * 2014-06-13 2026-02-01 Bach Biosciences Llc FAP-activated medical materials and related uses
SG11201606876RA (en) 2015-03-04 2016-10-28 Gilead Sciences Inc Toll like receptor modulator compounds
SMT202500412T1 (it) 2016-01-11 2025-11-10 Innate Tumor Immunity Inc Dinucleotidi ciclici per il trattamento di condizioni associate all’attività di sting quali il cancro
US20210353652A1 (en) 2018-06-04 2021-11-18 Trustees Of Tufts College Tumor microenvironment-activated drug-binder conjugates, and uses related thereto

Similar Documents

Publication Publication Date Title
Peng et al. Herceptin-conjugated paclitaxel loaded PCL-PEG worm-like nanocrystal micelles for the combinatorial treatment of HER2-positive breast cancer
Lian et al. Functional peptide-based drug delivery systems
JP2025066807A (ja) 生体直交型組成物
Larson et al. Polymeric conjugates for drug delivery
Hamman et al. Oral delivery of peptide drugs: barriers and developments
Ding et al. HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug
Davoodi et al. Internalizing RGD, a great motif for targeted peptide and protein delivery: a review article
ES2711669A1 (es) Sistemas de liberacion de farmacos de acido polisialico y metodos
JP2023548136A5 (cg-RX-API-DMAC7.html)
Sorolla et al. Peptides, proteins and nanotechnology: a promising synergy for breast cancer targeting and treatment
US9314533B2 (en) Conformations of divergent peptides with mineral binding affinity
RS66103B1 (sr) Humanizovani specifični membranski antigen prostate (psma) i konjugati lekova antitela
Li et al. Recent advances in peptide-based therapeutic strategies for breast cancer treatment
JP7837558B2 (ja) 活性剤を送達する生体適合ポリマー薬物担体
Lee et al. Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy
Peng et al. Legumain protease-activated tuftsin-functionalized nanoparticles for dual-targeting TAMs and cancer chemotherapy
JP2023548310A (ja) Fap活性化血清半減期延長型治療用コンジュゲート
JP2020527556A5 (cg-RX-API-DMAC7.html)
Ruoslahti Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier
Wu et al. Inflammation-targeted drug delivery strategies via albumin-based systems
Jeswani et al. Recent advances in the delivery of chemotherapeutic agents
Su et al. Synergistic antitumor activity from two-stage delivery of targeted toxins and endosome-disrupting nanoparticles
JP2026510850A (ja) リンカー及びそれを使用したカップリング薬物、抗体薬物複合体並びにその応用
Zhao et al. Nanomaterials for acute myeloid leukemia therapy: current progress and future perspectives
Liang et al. Long-circulating protein-polymer conjugates: Advancing beyond PEGylated proteins